In the biggest buyout of 2022 so far, Pfizer has agreed to acquire Biohaven Pharmaceutical for US$148.50 per share in cash, representing a total transaction value of US$11.6 B. Biohaven’s lead marketed drug, Nurtec™ ODT (rimegepant), is a non-calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine and preventive treatment of episodic migraine. This agreement follows the collaboration announced in November 2021 which saw Pfizer acquire rights to commercialise rimegepant and zavegepant outside of the US and take a 2.6% stake in Biohaven.